Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia.

RA Vremans; J Geenen; AM Hovels; WG Goettsch; HGM Leufkens; Maiwenn Al

doi:10.1007/s40258-019-00496-1

Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia.

RA Vremans, J Geenen, AM Hovels, WG Goettsch, HGM Leufkens, Maiwenn Al

Health Technology Assessment (HTA)

Research output: Contribution to journal › Article › Academic › peer-review

9 Citations (Scopus)

8 Downloads (Pure)

Original language	English
Pages (from-to)	883-893
Number of pages	11
Journal	Applied Health Economics and Health Policy
Volume	17
DOIs	https://doi.org/10.1007/s40258-019-00496-1
Publication status	Published - 2019

Access to Document

10.1007/s40258-019-00496-1

REPUB_118364-OA.pdfFinal published version, 1.07 MB

http://hdl.handle.net/1765/118364

Cite this

@article{88e559b47d9c49338290667c2e36355d,

title = "Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia.",

author = "RA Vremans and J Geenen and AM Hovels and WG Goettsch and HGM Leufkens and Maiwenn Al",

year = "2019",

doi = "10.1007/s40258-019-00496-1",

language = "English",

volume = "17",

pages = "883--893",

journal = "Applied Health Economics and Health Policy",

issn = "1175-5652",

publisher = "Springer International Publishing AG",

}

TY - JOUR

T1 - Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia.

AU - Vremans, RA

AU - Geenen, J

AU - Hovels, AM

AU - Goettsch, WG

AU - Leufkens, HGM

AU - Al, Maiwenn

PY - 2019

Y1 - 2019

UR - https://link.springer.com/article/10.1007%2Fs40258-019-00496-1

U2 - 10.1007/s40258-019-00496-1

DO - 10.1007/s40258-019-00496-1

M3 - Article

SN - 1175-5652

VL - 17

SP - 883

EP - 893

JO - Applied Health Economics and Health Policy

JF - Applied Health Economics and Health Policy

ER -

Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia.

Access to Document

Other files and links

Cite this